U.S. Tobacco Stock News

Nurix Therapeutics recently amended its equity distribution agreement to allow sales of up to US$413.65 million of common stock through Piper Sandler under its existing shelf registration. This expanded at-the-market facility gives Nurix added funding flexibility, potentially affecting how investors assess its balance between capital needs and ownership dilution. We will now examine how this enlarged at-the-market capacity shapes Nurix’s investment narrative, particularly around funding...

In February 2026, Atlas Energy Solutions reported fourth-quarter 2025 revenue of US$249.43 million and a quarterly net loss of US$22.24 million, while full-year 2025 revenue rose to US$1.10 billion alongside a full-year net loss of US$50.30 million versus a profit the year before. Despite swinging to losses, Atlas highlighted record utilization of its Dune Express system and new initiatives in power generation aimed at broadening its revenue base beyond traditional sand and logistics. We’ll...

In February 2026, Viridian Therapeutics reported fourth-quarter and full-year 2025 results showing modest revenue of US$132,000 for the quarter and US$70.85 million for the year, alongside higher net losses, while also filing a US$16.33 million common stock shelf registration tied to an ESOP-related offering and presenting at a major healthcare conference. Beyond the financials, investor attention centers on Viridian’s progress toward potential FDA approval and commercial launch preparations...

What triggered the latest move in Distribution Solutions Group? Distribution Solutions Group (DSGR) is back in focus after its fourth quarter and full year 2025 earnings missed analyst expectations on both revenue and earnings, pressuring margins and sparking legal scrutiny following a sharp share price reaction. See our latest analysis for Distribution Solutions Group. The sharp post earnings drop has fed into a wider reset in expectations, with a 7 day share price return of 26.12% and a...

What just happened with Genworth Financial stock Genworth Financial (GNW) has drawn fresh attention after reporting fourth quarter and full year 2025 results, as well as completing a share buyback that retired more than 10 million shares. See our latest analysis for Genworth Financial. At a share price of US$8.43, Genworth’s short term share price returns, including a 1 month share price return of 6.64% decline and a year to date share price return of 6.02% decline, contrast with a 1 year...

In late February 2026, Vir Biotechnology announced a global collaboration with Astellas Pharma around its investigational prostate cancer therapy VIR-5500, alongside positive early Phase 1 data, a US$150,000,002 follow-on equity raise, new shelf registration and its 2025 earnings results. Together, the Astellas partnership economics, encouraging early VIR-5500 data and fresh equity capital appear to materially reshape Vir Biotechnology’s funding mix, oncology profile and long-term...

Why Immunovant is back on investors’ radar Immunovant (IMVT) has drawn fresh attention after completing enrollment in a potentially registrational IMVT-1402 trial for difficult rheumatoid arthritis, alongside a roughly US$550 million capital raise from institutional investors. See our latest analysis for Immunovant. At a share price of US$26.66, Immunovant has recently seen a 15.06% 90 day share price return and a 33.17% 1 year total shareholder return. This suggests momentum has built over...

Pentair stock snapshot and recent performance Pentair (PNR) has been on many watchlists after a period of weaker share performance, with the stock showing negative returns over the past week, month, and past 3 months despite a positive 1 year total return. See our latest analysis for Pentair. At a share price of $92.17, Pentair’s recent 1 day, 7 day and 90 day share price returns have been negative, while its 1 year and 3 year total shareholder returns remain positive, suggesting shorter term...

In February 2026, Agilent Technologies reported first-quarter 2026 sales of US$1,798 million, with net income of US$305 million, and raised full-year 2026 revenue guidance to a range of US$7.30 billion to US$7.50 billion while issuing new second-quarter revenue guidance of US$1,790 million to US$1,820 million. Management’s decision to increase full-year revenue guidance while first-quarter earnings per share were slightly lower than a year earlier highlights confidence in cost control and...

In early March 2026, Mobix Labs, Inc. reported new production purchase orders for its high-reliability electromagnetic interference protection components used in Gulfstream business jets and the U.S. Navy’s Tomahawk cruise missile program, alongside a change to its bylaws reducing the shareholder meeting quorum requirement to one-third of voting power. The fresh aerospace and defense orders underline Mobix Labs’ role as an already-qualified supplier embedded in mission-critical platforms...

NIQ Global Intelligence: Recent Price Moves and Business Snapshot NIQ Global Intelligence (NIQ) has drawn fresh attention after recent share price swings, with the stock down 2.5% over the past day, weaker over the past week, but positive over the past month. For investors looking at the consumer data and analytics space, NIQ sits in an interesting position. The company reports annual revenue of US$4,198.4m and a net loss of US$353.3m, while its value score stands at 6. Over the past 3...

The weak February U.S. jobs report, which showed a loss of 92,000 jobs and unemployment at 4.4%, triggered a 3.6% drop in Enova International (ENVA), highlighting investor concern around credit conditions and demand. See our latest analysis for Enova International. That jobs-driven drop comes after a tougher few weeks for the share price, with a 30 day share price return of a 14.6% decline and a year to date share price return of a 15.05% decline, even though the 1 year total shareholder...

If you are wondering whether Casella Waste Systems at around US$94.03 is a fair deal or a stretch, you are not alone. This article focuses squarely on what the current price might imply about value. The stock has moved 0.9% over the past week, while showing a 10.1% decline over 30 days, a 4.7% decline year to date, a 16.4% decline over 1 year, but gains of 24.7% over 3 years and 45.3% over 5 years. Recent price moves sit against a backdrop where investors are watching the waste and recycling...

Federal Signal (NYSE:FSS) reported record quarterly and full year results, with net sales and adjusted EPS at the highest levels in the company’s history. The company announced a meaningful dividend increase alongside these results. Federal Signal also appointed two experienced executives to its board of directors. Federal Signal, listed on the NYSE under ticker FSS, focuses on safety and environmental solutions, including equipment and systems used by municipal, industrial, and commercial...

Garmin (NYSE:GRMN) reported record revenue across all segments. The company announced a 17% increase in its dividend. Garmin unveiled a new US$500 million share repurchase program. The company launched an initiative to recognize local changemakers in running communities. Garmin is best known for its GPS, fitness, aviation, marine, and outdoor products. All its business segments are contributing to record revenue. For investors, the combination of diversified end markets and demand for...

If you are wondering whether Planet Fitness is starting to look interesting at current levels, you are not alone. A closer look at what you are paying for the business can help put the recent share price in context. The stock closed at US$78.66, with returns of a 4.2% decline over 7 days, a 14.1% decline over 30 days, a 28.3% decline year to date and a 19.2% decline over 1 year, which may have some investors rethinking both the risk and potential reward here. Recent news has focused on...

CorMedix Inc. has reported past fourth-quarter 2025 revenue of US$128.62 million and net income of US$14.02 million, capping a year in which full-year revenue reached US$311.71 million and net income swung to US$163.06 million from a prior loss. The company’s reiteration of 2026 net revenue guidance of US$300 million to US$320 million, alongside advancing late-stage trials for REZZAYO and other pipeline assets, highlights management’s focus on consolidating recent product gains while...

Dream Finders Homes (DFH) has drawn investor attention after recent trading left the stock at US$16.40, with declines over the past week, month, and past 3 months raising questions about what is priced in. See our latest analysis for Dream Finders Homes. At US$16.40, the recent 1 day, 7 day and 30 day share price returns of 4.93%, 9.24% and 16.20% respectively point to fading near term momentum. The 1 year total shareholder return of 35.36% contrasts with a 3 year total shareholder return of...

Palladyne AI (PDYN) is back in focus after reporting Q4 and full year 2025 results, along with a fresh look at its 2026 outlook that combines earnings, guidance and backlog updates in one announcement. See our latest analysis for Palladyne AI. The latest earnings and guidance update landed after a sharp run in the shares, with a 7 day share price return of 21.34% and a 90 day share price return of 55.94% that point to building momentum despite a 14.36% pullback in the last session. The 3 year...

In early March 2026, Renasant reported fourth-quarter 2025 results that beat analyst expectations, approved a US$0.23 per share quarterly dividend for payment on March 31, 2026, and disclosed an insider sale of 1,350 shares by EVP and Chief Accounting Officer Kelly Hutcheson. At the same time, investors grew more cautious about regional banks’ exposure to opaque private credit after a peer’s large loan write-off raised questions about hidden balance sheet risks across the sector. Against...

In late February 2026, Ducommun Incorporated reported fourth-quarter 2025 results showing sales of US$215.8 million and net income of US$7.44 million, while full-year 2025 sales rose to US$824.73 million alongside a net loss of US$33.94 million. The contrast between a profitable quarter and a loss-making year, with earnings per share swinging from US$2.13 to a US$2.27 loss, raises questions about what drove the weaker full-year performance beneath improving quarterly metrics. We’ll now...

In February 2026, RLJ Lodging Trust reported fourth quarter 2025 revenue of US$328.59 million and net income of US$0.43 million, alongside full-year 2025 revenue of US$1.35 billion and net income of US$28.51 million, both lower than the prior year. Despite completing a relatively small US$4.3 million share repurchase program covering 586,417 shares, the more striking development was the sharp fall in full-year earnings per share from continuing operations to US$0.01, highlighting pressure on...

Wave Life Sciences Ltd. reported fourth-quarter 2025 sales of US$17.24 million versus US$83.75 million a year earlier, with a net loss of US$53.18 million replacing prior net income, and full-year 2025 losses widening as revenues decreased. At the same time, Wave advanced its clinical and regulatory agenda by securing a late-breaking oral slot for WVE-006 at the American Thoracic Society conference and pursuing an accelerated approval pathway for alpha-1 antitrypsin deficiency, underscoring...

PureCycle Technologies reported full-year 2025 sales of US$8.36 million alongside a net loss of US$182.57 million, while its auditor stated there were no critical audit matters, alleviating previously raised going concern doubts in the latest 10-K filing.